MedPacto, Inc. (KOSDAQ:235980)
South Korea · Delayed Price · Currency is KRW 2,735.00
+5.00 (0.18%)
Sep 22, 2026, 3:30 PM KST
MedPacto Revenue
MedPacto had revenue of 1.05B KRW in the quarter ending June 30, 2026, with 24.97% growth. This brings the company's revenue in the last twelve months to 4.99B, up 293.41% year-over-year. In the year 2025, MedPacto had annual revenue of 3.90B.
Revenue (ttm)
4.99B
Revenue Growth
+293.41%
P/S Ratio
18.73
Revenue / Employee
89.19M
Employees
56
Market Cap
93.57B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.90B | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HLB Therapeutics | 64.45B |
| ORIENT BIO | 59.09B |
| Amicogen | 46.69B |
| GC Genome | 32.64B |
| Prestige BioPharma | 16.21B |
| Anterogen.Co.,Ltd. | 8.37B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |